▶ KPV · SUBTOPIC · DOSING LITERATURE

KPV Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of KPV. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for KPV reports the following route(s) of administration: Oral (preclinical), Subcutaneous (research), Topical (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of KPV.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for KPV of approximately Short (minutes) plasma · longer tissue retention reported. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of KPV. Refer to the original publication for full protocol detail.

Brzoska T, Luger TA, Maaser C, Abels C, Bohm M (2008) reports the KPV protocol used in Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases, published in Endocr Rev. PMID 18483175. See the source for the protocol-level dose range, frequency, and duration. link
Kannengiesser K, Maaser C, Heidemann J, et al. (2008) reports the KPV protocol used in Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease, published in Inflamm Bowel Dis. PMID 18067137. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ How does KPV work?

Proposed mechanisms include melanocortin receptor signaling (MC1R, MC5R) and direct intracellular inhibition of NF-kappaB activation. The molecule is small enough to cross epithelial barriers including the intestinal mucosa, enabling oral and topical research applications.

▶ What's the half-life of KPV?

Short plasma half-life (minutes). Tissue retention is reportedly longer. Research protocols use frequent dosing or topical/oral routes to maintain target-tissue exposure.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · 2-8 °C, 24 months

Reconstituted · 2-8 °C, 28 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Research-use only.

WADA · Not currently listed on the WADA Prohibited List (2026).

◀ KPV OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-25